Cencora Names Eva Boratto CFO as Cleary Retires
Event summary
- Eva Boratto appointed CFO of Cencora effective June 29, 2026, succeeding James Cleary.
- Boratto brings healthcare and consumer sector experience, including CFO roles at Bath & Body Works and CVS Health.
- Cencora reaffirms fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90.
- Long-term guidance maintained: 7-10% adjusted operating income growth and 10-14% adjusted diluted EPS growth.
The big picture
Cencora's appointment of Eva Boratto as CFO underscores its focus on financial discipline and strategic reinvestment, critical for a company at the center of the global pharmaceutical supply chain. Boratto's background in healthcare and consumer sectors, along with her experience in large-scale transformations, positions her to navigate Cencora's growth ambitions amid evolving market dynamics. With over $300 billion in annual revenue, Cencora's leadership transition comes at a pivotal time for executing its long-term growth strategy.
What we're watching
- Strategic Execution
- How Boratto's experience in cost savings and digital transformation will impact Cencora's pharmaceutical-centric strategy.
- Financial Discipline
- Whether Boratto can sustain the financial discipline she implemented at Bath & Body Works within Cencora's operations.
- Growth Priorities
- The pace at which Cencora advances its core growth priorities under new financial leadership.
Related topics